Links Page

Fu, C, et al. Clin Cancer Res 7: 4182-4194


This research paper describes the discovery of HP59, the tumor capillary lectin marker that is the target of the Group B Streptococcal toxin (GBS Toxin), CM101, the etiologic agent for "Early Onset Disease", and the biological that targets tumor neovasculature.

HP59 Wikipedia Page


Wikipedia page describing HP59, fully referenced.

Phase I Clinical Safety Trial for CM101

 

DeVore RF, Hellerqvist CG, Wakefield GB, Wamil BD, Thurman GB, Minton PA, Sundell HW, Yan H-P,

Carter CE, Wang Y-F, York GE, Zhang M-H, Johnson DH.: A phase I study of the antineovascularization drug

CM101. J Clin Canc Res, 3, 365-372 (1997).

Review on angiogenesis-vasculogenesis


 




Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma



Mary J. C. Hendrix, Elisabeth A. Seftor, Angela R. Hess & Richard E. B. Seftor



Nature Reviews Cancer 3411-421 (2003)